CYTR Stock Forecast and Price Target (CytRx Corporation stock)

CYTR Stock Trend

The stock lies in the lower of a wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $0.54 is broken, it will firstly indicate a stronger fall rate.

Given the current short-term trend, the stock is expected to fall -38.67% during the next 3 months and, with a 90% probability hold a price between $0.33 and $0.41 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-22	$0.54	$0.60	$0.66
2021-09-23	$0.53	$0.59	$0.65
2021-09-24	$0.52	$0.58	$0.64
2021-09-27	$0.52	$0.58	$0.64
2021-09-28	$0.51	$0.57	$0.63
2021-09-29	$0.50	$0.56	$0.62
2021-09-30	$0.50	$0.56	$0.62
2021-10-01	$0.49	$0.55	$0.61
2021-10-04	$0.48	$0.54	$0.60
2021-10-05	$0.48	$0.54	$0.60
2021-10-06	$0.47	$0.53	$0.59
2021-10-07	$0.46	$0.52	$0.58
2021-10-08	$0.46	$0.52	$0.58
2021-10-11	$0.45	$0.51	$0.57
2021-10-12	$0.44	$0.50	$0.56
2021-10-13	$0.44	$0.50	$0.56
2021-10-14	$0.43	$0.49	$0.55
2021-10-15	$0.42	$0.48	$0.54
2021-10-18	$0.42	$0.48	$0.54
2021-10-19	$0.41	$0.47	$0.53
2021-10-20	$0.40	$0.46	$0.52
2021-10-21	$0.40	$0.46	$0.52
2021-10-22	$0.39	$0.45	$0.51
2021-10-25	$0.38	$0.44	$0.50
2021-10-26	$0.38	$0.44	$0.50
2021-10-27	$0.37	$0.43	$0.49
2021-10-28	$0.36	$0.42	$0.48
2021-10-29	$0.36	$0.42	$0.48
2021-11-01	$0.35	$0.41	$0.47
2021-11-02	$0.34	$0.40	$0.46

About CytRx Corporation

CytRx CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The companys product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!